Pharma Companies
Maximize clinical trial efficiency with better inclusion/exclusion criteria.
De-risk your clinical trials by tracking how trial participants' genomic profiles react to new therapeutics.
Universities and Institutes
Expand the frontiers of neurologic disease research – uncover the full RNA ecosystem behind lifestyle factors and health.
Diagnostics Companies
Generate new revenue streams with a view to developing this RUO test into an IVD.
The precedent is set: Genomic tests are getting adopted and reimbursed by payors.
Laboratories
Optimize the utilization of your NGS sequencers while generating revenue. Our product fits seamlessly into current lab workflows, no new hardware required – the FBB Test works on standard NGS sequencers.
Pharma Research
An innovative research tool to elevate your medical discoveries to the next level
